One of the Nation’s Largest Public Healthcare Systems Joins Caris Centers of Excellence for Precision Medicine Network to Advance Tumor Profiling and Broaden Access to Precision Medicine
IRVING, Texas, August 8, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced that Memorial Healthcare System, one of the largest public healthcare systems in the nation, has joined the Caris Centers of Excellence for Precision Medicine Network™ (Network).
“Memorial Healthcare is recognized as one of Florida’s leading healthcare systems, and is a national leader in quality care and patient satisfaction. I am very excited to welcome them to the Centers of Excellence Network”, said Dr. John Marshall, Chairman of the Network, Professor of Medicine and Oncology at Georgetown University School of Medicine, and Chief of Hematology/Oncology at Georgetown Lombardi Comprehensive Cancer Center. “The Network continues to expand with both academic and community cancer centers collaborating to provide access to the highest quality genomic and proteomic profiling for patients.”
As a Network member, Memorial Healthcare System will actively participate in the development of standards of care and best practices for integrating molecular profiling in oncology practice, while also striving to increase widespread adoption and patient access to personalized medicine in clinical settings. Memorial Healthcare System will also leverage Caris’ multiple-technology tumor profiling service, Caris Molecular Intelligence®, to enable the practice of precision medicine by identifying therapy options and clinical trial opportunities based on the unique characteristics of a patient’s tumor.
“We are excited to join the Caris Precision Medicine Network and expand access to premier tumor profiling for patients across Florida,” said Dr. Luis E. Raez, Medical Director of Memorial Cancer Institute, the cancer institute of Memorial Health Care System. “We are also eager to join the collective effort of the Network to capture and track protein and genomic information with matched clinical data on a massive level to create a robust genomic foundation and inform guidelines and standards of care for tumor profiling.”
Caris Molecular Intelligence, a service that correlates molecular data from a tumor with biomarker and drug associations from the latest clinical and scientific cancer literature, is the key technology platform used across the Network to enable the delivery of precision medicine. This information is used to help inform treatment decisions by identifying therapies that have the potential to be most effective and to rule out those that are less likely to work, based on the unique molecular characteristics of an individual patient’s cancer. Caris Molecular Intelligence is a patented and proprietary offering that uses multiple technology platforms combined with sophisticated bioinformatics to develop clinically actionable reports for more than 95,000 patients to date.
About Caris Life Sciences®
Founded by David D. Halbert in 2008, Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. With more than 95,000 patients profiled, Caris Molecular Intelligence® (CMI) the company’s patented and proprietary product offering, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Caris Molecular Intelligence uses a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor. CMI then connects the biomarker data generated from the tumor with biomarker-drug associations supported by the evidence and in relevant clinical literature through the Company’s proprietary bioinformatics rules engine. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients utilizing CMI, and has observed that patients treated with drugs consistent with CMI’s recommendations based upon the patient’s tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.
About Memorial Healthcare System
Memorial Healthcare System (MHS) is one of the largest public healthcare systems in the country and a national leader in quality care and patient satisfaction. Its facilities include Memorial Regional Hospital, Memorial Regional Hospital South, Joe DiMaggio Children’s Hospital, Memorial Hospital West, Memorial Hospital Miramar, Memorial Hospital Pembroke and Memorial Manor nursing home. MHS has been recognized as one of Modern Healthcare magazine’s “Best Places to Work in Healthcare,” Florida Trend’s “Florida’s Best Companies to Work For,” and Becker’s Hospital Review’s “150 Great Places to Work in Healthcare.” For more information, please visit www.mhs.net.
Caris Life Sciences
Media Relations & Corporate Affairs
Memorial Healthcare System